Stereotaxis
Stereotaxis develops robotic cardiology instrument navigation systems that enhances the treatment of arrhythmias and coronary diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | $8.5m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 32 % | (20 %) | (5 %) | 1 % | 28 % | 43 % | 62 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (43 %) | (67 %) | (79 %) | (88 %) | (23 %) | (9 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (31 %) | (65 %) | (77 %) | (89 %) | (60 %) | (33 %) | (5 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 29 % | 38 % | 38 % | 36 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Stereotaxis is a leading MedTech company specializing in innovative robotic technologies for the treatment of arrhythmias. The company operates in the healthcare sector, providing advanced robotic catheter ablation systems that enable precise and safe treatment of heart rhythm disorders. Stereotaxis primarily serves healthcare professionals, including physicians and hospitals, who are involved in the treatment of arrhythmias. The company’s business model revolves around the development, manufacturing, and sale of its robotic systems, as well as providing ongoing support and maintenance services. Revenue is generated through the sale of these systems and associated services. Stereotaxis is recognized for its Robotic Magnetic Navigation (RMN) System, which has been successfully implemented in various healthcare facilities, enhancing the precision and safety of arrhythmia treatments. The company continues to innovate and expand its market presence, aiming to improve patient outcomes and advance the field of endovascular treatment.
Keywords: Robotic Catheter Ablation, Arrhythmia Treatment, MedTech, Healthcare, Precision, Safety, Physicians, Hospitals, RMN System, Endovascular Treatment.
Tech stack
Investments by Stereotaxis
Edit